Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma: Key Updates From the Annual Hematology Meeting
No se pudo agregar al carrito
Solo puedes tener X títulos en el carrito para realizar el pago.
Add to Cart failed.
Por favor prueba de nuevo más tarde
Error al Agregar a Lista de Deseos.
Por favor prueba de nuevo más tarde
Error al eliminar de la lista de deseos.
Por favor prueba de nuevo más tarde
Error al añadir a tu biblioteca
Por favor intenta de nuevo
Error al seguir el podcast
Intenta nuevamente
Error al dejar de seguir el podcast
Intenta nuevamente
Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma: Key Updates From the Annual Hematology Meeting
-
Narrado por:
-
De:
Acerca de esta escucha
In this episode, Shaji K. Kumar, MD, reviews key data on bispecific antibodies used to treat patients with relapsed/refractory multiple myeloma recently presented at the 2024 annual American Society of Hematology meeting, including:
- Early results with teclistamab combined with anti-CD38 therapy
- Real-world data with teclistamab including its use after other BCMA-targeted therapies
- Talquetamab as bridging therapy to BCMA-targeted CAR T-cell therapy
- Evaluation of prophylactic tocilizumab for cytokine-release syndrome associated with bispecific antibody therapy
Presenter:
Shaji K. Kumar, MD
Mark and Judy Mullins Professor of Hematologic Malignancies
Consultant, Division of Hematology
Professor of Medicine
Chair, Myeloma, Amyloidosis and Dysproteinemia Group
Research Chair, Division of Hematology
Associate Chair for Research, Department of Medicine
Mayo Clinic
Rochester, Minnesota
Link to full program:
https://bit.ly/40bjFCZ
Todavía no hay opiniones